The Impact of PEGylation on Biological Therapies

By F. Veronese, A. Mero. BioDrugs, 2012

932 citations recorded by the source corpus.

Subfields: Biomaterials, Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/6f3f5b2ec2e06855083758f69a51245186314499

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. David R. Kryscio
2. William B. Liechty
3. Nicholas A. Peppas
4. Stefan Schreiber
5. B. V. Slaughter

In Pediatrics, Perinatology and Child Health

1. Stefan Schreiber

In Public Health, Environmental and Occupational Health

1. Nicholas A. Peppas
2. Stefan Schreiber

Citations in the corpus

• Therapeutic antibodies for autoimmunity and inflammation (2010, background): “Several PEGylated proteins are licensed for human therap”
• Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo (2018, background): “The advantages of PEGylation include reduced non-specific uptake in tissue, reduced cell toxicity, increased blood half-life and reduced proteolytic degradation [148,167].”
• Certolizumab pegol for the treatment of Crohn’s disease (2011, background): “The PEGylation of a biological molecule changes its physical and chemical properties to improve its pharmacokinetic behavior, typically improving solubility, increasing drug stability and decreasing immunogenicity [Veronese and Mero, 2008].”
• Polymers for Drug Delivery Systems (2010, background): “The impact of PEGylation on pharmaceuticals has been extensively reviewed elsewhere (83, 92, 104).”